Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-13
2009-11-17
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S081000
Reexamination Certificate
active
07618980
ABSTRACT:
The present application provides pyrrolo(oxo)isoquinolines as modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.
REFERENCES:
patent: 4268513 (1981-05-01), Shapiro
patent: 2003/0187254 (2003-10-01), Perry et al.
patent: WO 99/09025 (1999-02-01), None
patent: WO 03/014121 (2003-02-01), None
patent: WO 2004/065351 (2004-08-01), None
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
Caplus English Abstract DN 140:146029 Viranyi Andrea et al, 2003.
Caplus English Abstract DN 140:146025 Nyerges et al, 2003.
Caplus English Abstract Achini Roland, DN 96: 104021, 1981, vol. 64, Issue7, pp. 2203-2218. See RN #80897-02-5P.
U.S. Appl. No. 11/180,268, filed Jul. 13, 2005, Fevig et al.
Chojnacka-Wójcik, E. et al., “Involvement of 5-HT2CReceptors in the m-CPP-Induced Antinociception in Mice”, Pol. J. Pharmacol., vol. 46, pp. 423-428 (1994).
Cryan, J.F. et al., “Antidepressant-Like Behavioral Effects Mediated by 5-Hydroxytryptamine2CReceptors”, The Journal of Pharmacology and Experimental Therapeutics, vol. 295, No. 3, pp. 1120-1126 (2000).
Di Matteo, V. et al., “Role of 5-HT2Creceptors in the control of central dopamine function”, Trends in Pharmacological Sciences, vol. 22, No. 5, pp. 229-232 (2001).
Grottick, A.J. et al., “Activation of 5-NT2Creceptors reduces the locomotor and rewarding effects of nicotine”, Psychopharmacology, vol. 157, pp. 292-298 (2001).
Grottick, A.J. et al., “Studies to Investigate the Role of 5-HT2CReceptors on Cocaine- and Food- Maintained Behavior”, The Journal of Pharmacology and Experimental Therapeutics, vol. 295, No. 3, pp. 1183-1191 (2000).
Hoffman, B.J. et al., “Distribution of serotonin 5-HT1Creceptor mRNA in adult rat brain”, FEBS Letters, vol. 247, No. 2, pp. 453-462 (1989).
Hoyer, D. et al., “VII. International Union of Pharmacology Classification of Receptors for 5- Hydroxytryptamine (Serotonin)”, Pharmacological Reviews, vol. 46, No. 2, pp. 157-203 (1994).
Jones, K. et al., “Intramolecular Reactions Using Amide Links: Aryl Radical Cyclisation of Silylated Acryloylanilides”, Tetrahedron Letters, vol. 35, No. 41, pp. 7673-7676 (1994).
Mazzola-Pomietto, P. et al., “Evidence thatm-chlorophenylpiperazine-induced hyperthermia in rats is mediated by stimulation of 5-HT2Creceptors”, Psychopharmacology, vol. 123, pp. 333-339 (1996).
Millan, M.J. et al., “5-HT2Creceptors mediate penile erections in rats: actions of novel and selective agonists and antagonists”, European Journal of Pharmacology, vol. 325, pp. 9-12 (1997).
Nonogaki, K. et al., “Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2Creceptor gene”, Nature Medicine, vol. 4, No. 10, pp. 1152-1156 (1998).
Nyerges, M. et al., “A Convenient Synthesis of Pyrrolo[3,4-c]quinolines”, Heterocyclic Communications, vol. 9, No. 3, pp. 239-242 (2003).
Rittenhouse, P.A. et al., “Evidence that ACTH Secretion Is Regulated by Serotonin2A/2C(5-HT2A/2C) Receptors”, The Journal of Pharmacology and Experimental Therapeutics, vol. 271, No. 3, pp. 1647-1655 (1994).
Sharpley, A.L. et al., “Slow Wave Sleep in Humans: Role of 5-HT2Aand 5-HT2CReceptors”, Neuropharmacology, vol. 33, No. 3/4, pp. 467-471 (1994).
Vickers, S.P. et al., “Comparative effects of continuous infusion ofmCPP, Ro 60-0175 andd- fenfluramine on food intake, water intake, body weight and locomotor activity in rats”, British Journal of Pharmacology, vol. 130, pp. 1305-1314 (2000).
Vickers, S.P. et al., “Evidence that hypophagia induced byd-fenfluramine andd-norfenfluramine in the rat is mediated by 5-HT2Creceptors”, Neuropharmacology, vol. 41, pp. 200-209 (2001).
Vickers, S.P. et al., “Reduced satiating effect ofd-fenfluramine in serotonin 5-HT2Creceptor mutant mice”, Psychopharmacology, vol. 143, pp. 309-314 (1999).
Virányi, A. et al., “A Convenient Synthesis of Pyrrolo[3,4-c]quinolines”, Synthesis, No. 17, pp. 2655-2660 (2003).
Roy et al., “Studies on the Reaction of Benzoyl Peroxide with NN-Disubstituted Aromatic Amines and Other Related Compounds. Part IV. A Novel Formation of 1,2,3,4-Tetrahydroquinoline Derivatives”, Journal of the Chemical Society, Section C: Organic Chemistry, Chemical Society, Letchworth, GB, Jan. 1, 1969, pp. 1886-1891.
Cappelli et al., “Novel Potent 5-HT3 Receptor Ligands Based on the Pyrrolidone Structure: Synthesis, Biological Evaluation, and Computational Rationalization of the Ligand-Receptor Interaction Modalities”, Bioorganic & Medicinal Chemistry, vol. 10, 2002, pp. 779-801.
Achini, “215. Synthesis of Phenyl- and Benzyl-Substituted Pyrrolidones and of a Piperidine by intramolecular C-Alkylation. Synthons for Tricyclic Skeletons”, Helvetica Chimica ACTA, vol. 64, No. 7, Jan. 1, 1981 pp. 2203-2218.
Ahmad Saleem
Feng Jianxin
Fevig John M.
Bogie Terence J.
Bristol--Myers Squibb Company
Desai Rita J
LandOfFree
Pyrrolo(oxo)quinolines as 5HT ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolo(oxo)quinolines as 5HT ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolo(oxo)quinolines as 5HT ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4121997